5.74  -0.06 (-1.03%)		04-26 16:00
Open: 5.74 High: 5.74 Volume: 409		Pre. Close: 5.8 Low: 5.74 Market Cap: 270(M)

Short term
Mid term
Targets	6-month :	7.11	1-year :	7.8
Resists	First :	6.08	Second :	6.67
Pivot price	5.82
Supports	First :	5.13	Second :	4.26
MAs	MA(5) :	5.79	MA(20) :	5.92
	MA(100) :	6.7	MA(250) :	6.72
MACD	MACD :	-0.2	Signal :	-0.3
%K %D	K(14,3) :	51.1	D(3) :	47.8
RSI	RSI(14): 44.5
52-week	High :	11	Low :	1.75

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NBTX ] has closed above bottom band by 43.2%. Bollinger Bands are 3.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.75 - 5.78	5.78 - 5.8
Low:	5.67 - 5.7	5.7 - 5.73
Close:	5.68 - 5.74	5.74 - 5.79

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Fri, 26 Apr 2024
Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen Partnership - TipRanks.com - TipRanks

Wed, 24 Apr 2024
Nanobiotix Sa ADR Reports Promising 2023 Progress - TipRanks.com - TipRanks

Wed, 17 Apr 2024
Nanobiotix Sa ADR Sets Q4 and Full Year Results Date - TipRanks.com - TipRanks

Wed, 17 Apr 2024
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024 - GlobeNewswire

Thu, 11 Apr 2024
Nanobiotix Sa ADR Updates Share Capital Info - TipRanks.com - TipRanks

Thu, 11 Apr 2024
Baillie Gifford & Co. Acquires 932835 Shares of Nanobiotix S.A. (NASDAQ:NBTX) - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	47 (M)
Shares Float	21 (M)
Held by Insiders	0 (%)
Held by Institutions	19.6 (%)
Shares Short	50 (K)
Shares Short P.Month	43 (K)

EPS	-1.79
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-1.53
Profit Margin	0 %
Operating Margin	-770.6 %
Return on Assets (ttm)	-47.7 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	147.8 %
Gross Profit (p.s.)	0
Sales Per Share	0.14
EBITDA (p.s.)	-0.98
Qtrly Earnings Growth	0 %
Operating Cash Flow	-37 (M)
Levered Free Cash Flow	-25 (M)

PE Ratio	-3.21
PEG Ratio	0
Price to Book value	-3.76
Price to Sales	40.12
Price to Cash Flow	-7.34

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.